<DOC>
	<DOCNO>NCT00003290</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether standard radiation therapy effective high-dose radiation therapy treat patient prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness standard radiation therapy high-dose radiation therapy treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare local tumor control patient stage II III prostate cancer treat neoadjuvant androgen deprivation therapy standard v high-dose conformal radiotherapy . - Compare incidence biochemical failure ( prostate-specific antigen ( PSA ) great 2 ng/mL 6 month initiation radiotherapy PSA rise nadir level least 50 % ) , development metastasis , survival patient treat regimen . - Compare acute late radiation-induced side effect regimens patient population . - Compare aspects quality life , health economics , model normal tissue , tumor control patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord prostate-specific antigen , T stage , Gleason score . Patients randomize one two treatment arm . All patient receive neoadjuvant androgen deprivation luteinizing hormone-releasing hormone agonists every 4 week begin 3-6 month initiation radiotherapy continue completion radiotherapy . - Arm I : Patients undergo standard conformal radiotherapy 6.5 week . - Arm II : Patients undergo high-dose conformal radiotherapy 7.5 week . Quality life assess baseline , every 6 month 2 year , annually thereafter . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 800 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer T1bT3a , N0 , M0 ( stage II III ) Prostatespecific antigen least 50 ng/mL PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 11 g/dL Hepatic : Not specify Renal : Not specify Other : No significant past medical history would preclude radical radiotherapy No condition would preclude standard radiotherapy No hip prosthesis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No prior androgen deprivation therapy Radiotherapy : No prior pelvic radiotherapy Surgery : No prior radical prostatectomy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>